Enorama Pharma AB (ERMA) - Total Assets
Based on the latest financial reports, Enorama Pharma AB (ERMA) holds total assets worth Skr22.95 Million SEK (≈ $2.47 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ERMA total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Enorama Pharma AB - Total Assets Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's total assets have evolved over time, based on quarterly financial data. Check Enorama Pharma AB (ERMA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Enorama Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Enorama Pharma AB's total assets of Skr22.95 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 36.8% |
| Accounts Receivable | Skr3.21 Million | 38.9% |
| Inventory | Skr1.75 Million | 21.2% |
| Property, Plant & Equipment | Skr12.00K | 0.2% |
| Intangible Assets | Skr254.00K | 3.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ERMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enorama Pharma AB's current assets represent 96.8% of total assets in 2025, an increase from 0.7% in 2014.
- Cash Position: Cash and equivalents constituted 36.8% of total assets in 2025, up from 0.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 38.9% of total assets.
Enorama Pharma AB Competitors by Total Assets
Key competitors of Enorama Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Enorama Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.64 | 1.08 | 0.66 |
| Quick Ratio | 0.59 | 0.81 | 0.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-12.60 Million | Skr2.05 Million | Skr-7.16 Million |
Enorama Pharma AB - Advanced Valuation Insights
This section examines the relationship between Enorama Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.30 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -48.0% |
| Total Assets | Skr8.26 Million |
| Market Capitalization | $2.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Enorama Pharma AB's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enorama Pharma AB's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enorama Pharma AB (2014–2025)
The table below shows the annual total assets of Enorama Pharma AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.26 Million ≈ $889.12K |
-48.02% |
| 2024-12-31 | Skr15.89 Million ≈ $1.71 Million |
-53.78% |
| 2023-12-31 | Skr34.38 Million ≈ $3.70 Million |
-29.42% |
| 2022-12-31 | Skr48.72 Million ≈ $5.24 Million |
-4.34% |
| 2021-12-31 | Skr50.93 Million ≈ $5.48 Million |
+24.52% |
| 2020-12-31 | Skr40.91 Million ≈ $4.40 Million |
-3.94% |
| 2019-12-31 | Skr42.58 Million ≈ $4.58 Million |
+9.67% |
| 2018-12-31 | Skr38.83 Million ≈ $4.18 Million |
+150.72% |
| 2017-12-31 | Skr15.49 Million ≈ $1.67 Million |
+13.66% |
| 2016-12-31 | Skr13.63 Million ≈ $1.47 Million |
+48.63% |
| 2015-12-31 | Skr9.17 Million ≈ $986.62K |
+148.19% |
| 2014-12-31 | Skr3.69 Million ≈ $397.53K |
-- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.